Psilocybin-assisted psychotherapy for methamphetamine use disorder: A pilot open-label safety and feasibility study

This open-label pilot study (n=15) found that outpatient psilocybin-assisted psychotherapy (25mg) with motivational enhancement and acceptance and commitment therapy for methamphetamine use disorder was safe and feasible, with participants showing reduced methamphetamine use from a median of 12 days at screening to 0 days at day 28 and 2 days at day 90 post-treatment.

Abstract of Psilocybin-assisted psychotherapy for methamphetamine use disorder

“Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin-assisted psychotherapy for methamphetamine use disorder.

Design Single arm, open label pilot study.

Setting Outpatient public stimulant treatment program at St. Vincent’s Hospital, Sydney, Australia.

Participants We recruited 15 participants that were ≥25 years old, seeking treatment for methamphetamine use, using methamphetamine ≥4 days/month at screening, and without serious mental illness or contraindicated medical conditions or medications.

Intervention Participants received three preparatory psychotherapy sessions over two weeks before a single psilocybin dosing session (25 mg oral), followed by two integration psychotherapy sessions over one week. Psychotherapy included elements of motivational enhancement and acceptance and commitment therapy. Participants were followed for 90 days post psilocybin-assisted psychotherapy session.

Measurements Primary endpoints were safety (as measured by adverse events over the trial and vital signs during psilocybin dosing) and feasibility (as measured by enrolment and dropout rates), and secondary endpoints included measuring self-reported methamphetamine and other illicit drug use, drug craving, depression, anxiety, stress and quality of life measures.

Findings Of 56 participants pre-screened, 15 were eligible and enrolled, 14 completed the intervention and 13 completed 90-day post-dose follow-up.”. No serious adverse events (AEs) occurred, and the seven treatment related AEs were self-limiting and mild to moderate in severity. AEs included hypertension during the dosing session and headache (n = 4), nausea (n = 1) and noise sensitivity (n = 1) within the week following the dose. Methamphetamine use (over the prior 28 days) was observed to be lower at screening (median 12 days, IQR 7–16, n = 15) relative to day 28 (median 0 days, IQR 0–2, n = 13) and 90 (median 2 days, IQR 1–4, n = 14) post psilocybin. Methamphetamine craving was also observed to be lower while quality of life, depression, anxiety, and stress were observed to be higher at days 28 and 90 follow-up relative to baseline.

Conclusions Psilocybin assisted psychotherapy for methamphetamine use disorder was feasible to implement in an outpatient setting and did not appear to generate safety concerns. A larger randomised controlled trial is required to confirm efficacy and safety.”

Authors: Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky & Jonathan Brett

Summary of Psilocybin-assisted psychotherapy for methamphetamine use disorder